NCT01744912 Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies Status TERMINATED Phase PHASE1
NCT01728207 Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL Status TERMINATED Phase PHASE1
NCT01724346 Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Status COMPLETED Phase PHASE3
NCT01722487 Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL Status COMPLETED Phase PHASE3
NCT01699152 Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Status COMPLETED Phase PHASE1
NCT01682616 A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Status COMPLETED Phase PHASE1
NCT01650727 A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974) Status COMPLETED Phase PHASE1
NCT01611090 A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Status COMPLETED Phase PHASE3
NCT01578707 A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Status COMPLETED Phase PHASE3
NCT01497496 Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Status COMPLETED Phase PHASE2
NCT01496976 Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL Status COMPLETED Phase PHASE2
NCT01484015 Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia Status COMPLETED Phase PHASE1
NCT01446900 R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma Status TERMINATED Phase PHASE2
NCT01419691 Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) Status COMPLETED Phase PHASE2
NCT01400685 Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL Status COMPLETED Phase PHASE1
NCT01351896 Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT01306643 Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma Status COMPLETED Phase PHASE1/PHASE2
NCT01292135 Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL) Status COMPLETED Phase PHASE1